[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-detail-344685-en":59,"doc-seo-344685-105":98},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":5,"data":60},{"doc_id":61,"user_id":62,"nickname":63,"user_avatar":64,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":66,"doc_content":67,"file_id":68,"file_url":69,"file_type":70,"file_size":71,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":72,"language":73,"language_code":74,"site_id":75,"html_lang":74,"table_of_contents":76,"faqs":77,"seo_title":78,"seo_description":66,"update_tm":79,"read_time":41,"preview_page_count":19,"preview_urls":80},344685,687197100911,"Himbo","https://ap-avatar.wpscdn.com/avatar/a000239b6f1da00475?x-image-process=image/resize,m_fixed,w_180,h_180&k=1785132997149421697","Migrastatic therapy as a potential game-changer in adaptive cancer treatment","Adaptive therapy counteracts cancer resistance by dynamically adjusting dosing and timing based on tumor response, yet current protocols do not include migrastatics that specifically inhibit metastasis. This study integrates migrastatics into adaptive therapy using a spatial game-theoretic model. Results show that combining adaptive therapy with migrastatics delays metastasis onset and lowers both the number and size of metastases across most scenarios. The approach extends time to first metastasis while increasing overall efficacy by targeting resistance evolution and metastatic spread.","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nMigrastatic therapy as a potential game-changer in adaptive cancer treatment  \nKatharina Schneider1,5, Louise Spekking2,5, SepinoudAzimi2, Barbora Peltanová3, Daniel Rösel3, Joel S. Brown4, RobertA. Gatenby4, Jan Brábek3 & Kateřina Staňková2􀀍  \nAdaptive therapy, which anticipates and counters the evolution of resistance in cancer cells, has gained significant traction, especially following the success of the Zhang et al.’s protocol in treating metastatic castrate-resistant prostate cancer. While several adaptive therapies have now advanced to clinical trials, none currently incorporates migrastatics, i.e. treatments designed to inhibit cancer cell metastasis. In this study, we propose integrating migrastatics into adaptive therapy protocols and evaluate its potential benefits through a spatial game-theoretic model. Our results demonstrate that combining adaptive therapy with migrastatics effectively delays the onset of metastases and reduces both the number and size of metastases in most cancer scenarios analyzed. Including migrastaticsto adaptive therapy not only extends the time to the first metastasis, but also enhances the overall efficacy of adaptive therapies. Our findings suggest a promising new direction for cancer treatment, where adaptive therapy, in combination with migrastatic agents, can target both the evolution of resistance and the metastatic spread of cancer cells.  \nCancer represents the second leading cause of death worldwide. Moreover, recent trends show that cancer may become the first leading cause of death by 20301,2. Cancer treatment typically targets uncontrolled cancer cell proliferation with the aim to eradicate tumors3–5.  \nIn standard of care, patients are typically given the maximum tolerated dose (MTD), which is the highest dose that a mean patient can handle without experiencing intolerable toxicity4,6,7. While MTD-based therapy offers survival benefits, it often comes with severe side effects. Moreover, recurrence is almost inevitable due to the emergence of therapeutic resistance8–12. To address these challenges, adaptive therapy (AT), also known as evolutionary therapy, has been proposed13–20. AT involves adjusting treatment dosing and timing based on cancer’s response to therapy. Mathematical models informed by known cancer biology and data have been crucial in its development5, 16, 18,21–23. Often, AT aims at maintaining a sufficient population of drug-sensitive cells, enabling them to outcompete drug-resistant cells when treatment is not applied, and hereby control the tumor burden longer. A pilot example of AT is Zhang et al.’s protocol in metastatic castrate-resistant prostate cancer (mCRPC)24,25. In this clinical trial, mCRPC is treated with MTD until the total tumor burden is halved compared to its initial size. Upon reaching this threshold, the treatment is stopped and the tumor is allowed toregrow to its original size, allowing for competition between drug-sensitive and resistant cells. When the total tumor burden reaches its initial size, treatment with MTD is reinstated and a new treatment cycle begins. Zhang et al.’s protocol aims to control the tumor burden through limiting the development of uncontrollable drug resistance rather than cancer eradication and nearly triples patients’ time to progression 24,25.  \nExisting AT protocols aim at tumor containment, control or eradication16, 18,21,22,24,26, and they do not target spread of the disease. However, up to 90% of mortality in solid tumors is due to metastasizing rather than cancer growth alone27,28. In order for the primary tumor to successfully metastasize, cancer cells need to complete a number of sequential events, the so-called invasion-metastatic cascade29–31.  \nConventional cytotoxic and/or cytostatic therapeutics target uncontrollable proliferation, which ultimately results in Darwinian selection of resistant clones within the tumor32. These ","cbCaib59PJLI9piJ","https://ap.wps.com/l/cbCaib59PJLI9piJ","pdf",3101932,12,"English","en",105,"# Introduction\n## Rationale: standard-of-care dosing and resistance\n## Adaptive therapy (AT) and the Zhang et al. protocol\n## Metastatic spread and invasion-metastatic cascade\n# Migrastatics as a new therapeutic approach","[{\"question\":\"What gap in adaptive therapy motivates this study?\",\"answer\":\"Existing adaptive therapy protocols aim to contain, control, or eradicate tumors but do not target disease spread via metastasis, and they do not incorporate migrastatics.\"},{\"question\":\"How are migrastatics different from cytotoxic or cytostatic treatments?\",\"answer\":\"Migrastatics target invasion and migration mechanisms, reducing cancer cell motility to prevent metastasis, rather than directly killing or halting proliferation.\"},{\"question\":\"What does the study conclude about the benefits of combining AT with migrastatics?\",\"answer\":\"The combination delays the onset of metastases and reduces both the number and size of metastases in most analyzed cancer scenarios, extending time to the first metastasis and improving overall efficacy.\"}]","Migrastatic therapy as a potential game-changer in adaptive cancer treatment | PDF",1790054919,[81,85,89,94],{"page_no":8,"url":82,"width":83,"height":84},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d259575aec70fd99bbdde7ee211bd78d.webp",983,1291,{"page_no":14,"url":86,"width":87,"height":88},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fce4fd83481d8a0f84abddc73ed1dc4e.webp",982,1290,{"page_no":90,"url":91,"width":92,"height":93},3,"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d26788a4855cd74bc24a5fbb0e67b832.webp",981,1289,{"page_no":19,"url":95,"width":96,"height":97},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b4589df54a4b607a097730eb53d5d642.webp",980,1287,{"code":4,"msg":99,"data":100},"ok",{"site_id":75,"language":74,"slug":101,"title":65,"keywords":102,"description":66,"schema_data":103,"social_meta":156,"head_meta":158,"extra_data":160,"updated_unix":161},"migrastatic-therapy-as-a-potential-game-changer-in-adaptive-cancer-treatment","",{"@graph":104,"@context":155},[105,118,138],{"@type":106,"itemListElement":107},"BreadcrumbList",[108,112,114,116],{"item":109,"name":110,"@type":111,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":113,"name":9,"@type":111,"position":14},"https://docshare.wps.com/document/",{"item":115,"name":40,"@type":111,"position":90},"https://docshare.wps.com/document/research-report/",{"item":117,"name":65,"@type":111,"position":19},"https://docshare.wps.com/document/migrastatic-therapy-as-a-potential-game-changer-in-adaptive-cancer-treatment/344685/",{"url":117,"name":65,"@type":119,"image":120,"author":125,"headline":65,"publisher":127,"fileFormat":130,"inLanguage":74,"description":66,"dateModified":131,"datePublished":132,"encodingFormat":130,"isAccessibleForFree":133,"interactionStatistic":134},"DigitalDocument",{"url":121,"@type":122,"width":123,"height":124},"https://docshare.wps.com/thumbnails/migrastatic-therapy-as-a-potential-game-changer-in-adaptive-cancer-treatment/344685.png","ImageObject",300,407,{"name":63,"@type":126},"Person",{"url":109,"name":128,"@type":129},"DocShare","Organization","application/pdf","2026-11-06","2026-09-22",true,{"@type":135,"interactionType":136,"userInteractionCount":39},"InteractionCounter",{"@type":137},"ViewAction",{"@type":139,"mainEntity":140},"FAQPage",[141,147,151],{"name":142,"@type":143,"acceptedAnswer":144},"What gap in adaptive therapy motivates this study?","Question",{"text":145,"@type":146},"Existing adaptive therapy protocols aim to contain, control, or eradicate tumors but do not target disease spread via metastasis, and they do not incorporate migrastatics.","Answer",{"name":148,"@type":143,"acceptedAnswer":149},"How are migrastatics different from cytotoxic or cytostatic treatments?",{"text":150,"@type":146},"Migrastatics target invasion and migration mechanisms, reducing cancer cell motility to prevent metastasis, rather than directly killing or halting proliferation.",{"name":152,"@type":143,"acceptedAnswer":153},"What does the study conclude about the benefits of combining AT with migrastatics?",{"text":154,"@type":146},"The combination delays the onset of metastases and reduces both the number and size of metastases in most analyzed cancer scenarios, extending time to the first metastasis and improving overall efficacy.","https://schema.org",{"og:url":117,"og:type":157,"og:title":65,"og:site_name":128,"og:description":66},"article",{"robots":159,"canonical":117},"index,follow",{"doc_id":61,"site_id":75},1791221018]